



Press Release

Poxel Provides YE15 Cash and Turnover Figures

Lyon, France, January 28, 2016 – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced its cash position and its turnover for the fiscal year 2015.

As of December 31st, 2015, the cash and cash equivalents amounted to €42.4 million* compared to €10.3 million on December 31st, 2014.

As expected, Poxel did not generate significant revenues in 2015.

These figures are consistent with the Company's expectations and its growth strategy, which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.

*unaudited

Next financial press release: Year Full-Year Financial Statement, March 31st, 2016

About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

Contacts

Investor relations / Media - EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
smay@macbiocom.com
+ 49 89 2424 3494 or + 49 172 861 8540

Investor relations / Media - France

NewCap
Florent Alba/Nicolas Mériegeau
poxel@newcap.fr
+ 33 1 44 71 98 55